Drug
CR8020
CR8020 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
withdrawn267%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge
NCT01938352
withdrawnphase_1
A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants
NCT02015533
withdrawnphase_2
Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection
NCT01992276
Clinical Trials (3)
Showing 3 of 3 trials
NCT01938352Phase 2
Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge
NCT02015533Phase 1
A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants
NCT01992276Phase 2
Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3